Background
During pregnancy and lactation, medications given to mothers to treat medical conditions have the potential to impact the health and development of the fetus or infant. Women are often advised to protect their breastfed infant by avoiding the medication or not feeding the infant the affected milk. Although the decision to expose the fetus to a medication during pregnancy may be considered unavoidable, and therefore ethically defensible, exposing an infant to medication through human milk creates a unique ethical dilemma given that many stakeholders consider infant formula to be a reasonable alternative. Pharmaceutical companies may consider that testing their medications among women who are pregnant or breastfeeding is too risky, preferring to take the alternative approach of advising that parents who are pregnant or breastfeeding should not use their product. This approach of risk avoidance has directly contributed to a lack of evidence pertaining to the safety and efficacy of many medications during pregnancy and lactation and resulted in clinicians prescribing medications to this population "off-label." The purpose of this article is to address ethical issues that should be considered in the development of evidence as well as decision making about medication use in breastfeeding women when viewed from a public health perspective.
Conceptual Framework
The goals of public health are the empowerment of healthy people in healthy communities. Public health ethics relates to moral implications of activities aimed at maintaining and improving population health (Abbasi et al., 2018) . The social ecological model (SEM) provides an effective approach to public health by using a combination of interventions from all elements of the model (Golden & Earp, 2012) . The five elements of the SEM are individual, interpersonal, community, organizational, and policy/enabling environment (McLeroy et al., 1988) . We applied this model in viewing the ethical practices surrounding the provision of medications to breastfeeding women as the outcome of interaction among these elements. The elements relevant for this article include the breastfeeding mother and her infant, the parent's social support network, health care professionals, health organizations, drug trial investigators, companies, and authorities (e.g., the U.S. Food and Drug Administration [FDA]).
Relevant Ethical Principles, Theories, and Concepts
In this article we have used the lens of ethical principles, an ethical theory, and ethical concepts used in public health. "Pivotal" ethical principles include respect for autonomy (ensuring, respecting, and acting in support of autonomous decisions), nonmaleficence (avoiding doing harm), beneficence (preventing or lessening harm, removing harmful conditions, and doing good), and justice (fairly distributing benefits and limiting burdens) (Beauchamp & Childress, 2013, pp. 15, 106-107, 151-152, 250) .
Utilitarian theory, which is focused on the good and bad consequences of actions (Beauchamp & Childress, 2013, p. 354) , is particularly relevant to public health, although some other ethical theories are also useful (e.g., the equalitarian theory of justice; Beauchamp & Childress, 2013, pp. 256-257 ; the capabilities theory of justice; Beauchamp & Childress, 2013, pp. 259-260;  and the well-being theory of justice; Beauchamp & Childress, 2013, pp. 260-261] ). Utilitarians endorse only one basic, or foundational, principle of ethics: the principle of utility. According to this principle, persons should act toward others in a way that creates the greatest "positive value over disvalue" (Beauchamp & Childress, 2013, p. 355 ). This is often described as doing the greatest good for the greatest number. The ethical concepts of fairness, equity, empowerment, capacity building, social responsibility, accountability for reasonableness, and informed consent are particularly relevant to public health (Abbasi et al., 2018) .
Ethical Issues Pertaining to Medication Use by Breastfeeding Parents

Prescription of Medications to Breastfeeding Parents Off-Label
Public health researchers embrace participation of affected populations in all stages of research from design to translation (Gopichandran et al., 2016) . In the past, pharmaceutical companies have avoided the issue of women's reproductive life and excluded pregnant and breastfeeding women from the drug development process (Shields & Lyerly, 2013) and then advised prescribers to avoid their medications in pregnancy and lactation. Therefore, when clinicians need to prescribe medications for breastfeeding parents, they do this off-label, often without evidence or guidance regarding optimal dosing or treatment recommendations (Byrne & Spong, 2019) .
The prescription of medications for breastfeeding parents off-label is the central issue we explore in this article. In a 2014 policy statement about the use of off-label medications in children, the American Academy of Pediatrics defined offlabel use as "use of a drug that is not included in the package insert (approved labeling)" (Frattarelli et al., 2014, p. 563) . In this article we use the term to describe the prescription of medication for use by breastfeeding parents that lacks approved labeling but has approved labeling for nonbreastfeeding women or when a medication is prescribed to treat a lactation-specific condition (e.g., insufficient milk supply) but is licensed for alternative indications.
The multilevel elements of the SEM interact to influence the off-label prescription of medications for breastfeeding parents. The previous exclusion of pregnant and breastfeeding women from drug trials has contributed to the lack of breastfeeding-specific drug information and government approvals for on-label prescription for breastfeeding parents. As a result, drug authorities (e.g., the FDA) have not approved many medications for on-label prescription for breastfeeding parents.
However, in the past couple of decades, we have seen a different approach. Multidisciplinary teams are beginning to work collaboratively to establish practice guidelines for medication use in women of reproductive age. One example where this is happening is the field of rheumatology, where "the demand for biologics has been increasing in female patients who have inflammatory diseases responsive to biologics and who wish to bear children" (Saito et al., 2019 (Saito et al., , p. 1505 . In response to patient need for evidence-based advice, a southeastern European expert meeting was held with a panel of clinicians from the region (Ntali et al., 2014) . The panel of specialists recommended rheumatology clinicians change their attitude from cautioning against pregnancy to embracing pregnancy.
When considering breastfeeding, the panel of specialists concluded "there are limited data on breastfeeding and use of biologics" (Ntali et al., 2014, p. 965) . However, in the past few years, case studies and case series are providing evidence that biologic (monoclonal antibody) therapy is compatible with breastfeeding (Matro et al., 2018; Saito et al., 2019) . As expected from pharmacokinetics of these large molecules, assays of human milk and infant serum confirmed low levels in human milk and undetectable levels in the breastfed infant (Saito et al., 2019) .
In 2005, the FDA recognized the need for improved labeling and research into medications and lactation, and a new Pregnancy and Lactation Labeling Rule was implemented in 2015 (US FDA, 2014; Wang et al., 2017) . The FDA held a public workshop in 2016 to discuss the safety evaluation of drugs and biological products used during lactation (Wang et al., 2017) . Stakeholders included individuals from academia, industry, the National Institutes of Health, and the FDA. Advocacy groups represented consumers. The two-day meeting was streamed live on the Internet. Wang et al. (2017) reported that the workshop had the following four major aims:
1. To review current approaches to the collection of data when drugs are used or expected to be used during lactation;
Key Messages
• • Breastfeeding women often need to take medication, yet this population has been neglected by pharmaceutical companies and researchers. • • When using utilitarian ethical theory, with its foundational principle of utility, one should do a risk-benefit assessment for each medication decision. The moral values of fairness and equity imply that infants should not be denied human milk and that current gaps in evidence should be addressed. • • The concepts of empowerment and capacity building should lead to improving health professionals' knowledge about evidence-based decision making regarding medicines and lactation and information provision to consumers. • • There exists a strong social responsibility to partner with consumers to generate greater evidence, and improve methods to communicate risks and benefits of medication use in lactation.
2. To discuss and consider novel approaches to improve the quality and quantity of data available to assess the safety of medications used during lactation and to inform the public of the potential risks of medication use during lactation; 3. To review and discuss strategies to communicate safety information related to maternal use of medications during lactation; and 4. To raise awareness and engage stakeholders regarding safety information related to maternal use of medications during lactation. (p. 737)
Similar workshops have emphasized the importance of the topic for human health and have helped to move the field forward in a way that improves research both conceptually and practically. Increasing public involvement in setting research agendas will improve knowledge translation and facilitate decision making in the future. The frameworks from implementation science can be used to design and conduct research that enables evidence-based practice to become routine (Gopichandran et al., 2016) . It is essential that clinicians understand the principles of medication use in lactation and do not immediately suggest that parents "pump and dump" (Cobb et al., 2015) .
The reality of prescribing for breastfeeding parents is that nearly all instances of medication use in lactation is off-label, creating additional ethical considerations. This is similar to pregnancy, for which it has been argued that the commonality with which medications are used off-label, often based on limited evidence, risks complacency in decision making among health professionals (Grzeskowiak & Mol, 2015) . Critical use of evidence is required to support all decisions. In some situations, routine use in an off-label manner is justified, and the utility principle upheld, based on available evidence demonstrating limited risk for infant harm.
However, in situations where evidence is limited, one could argue that there is a social responsibility for those making treatment recommendations to evaluate the outcomes of recommendations in order to inform subsequent evidence development. This is coupled with the ethical requirement to obtain informed consent when recommending off-label medication use for which evidence of safety is uncertain. This process risks overemphasizing the uncertainties and potential harms of medications and must be balanced against the risks of not breastfeeding.
Pregnant or Breastfeeding Parents' Participation in Drug Trials
As discussed, when clinicians prescribe medications for breastfeeding parents, they often do so with limited evidence, against the recommendations of pharmaceutical companies, and without the specific approval of regulators. A significant factor here is that for many years, drug trial investigators recruited only men (Cornelison & Clayton, 2017) . This routine exclusion of women was not a kindness to women. It meant that lack of recognition of sex differences in pharmacokinetics-for example, the increased risk of drug-induced changes in the QT interval in women-led to higher rates of medication side effects in women than in men (Franconi et al., 2019) . It was only in the 1990s that women became eligible for drug trials (Cornelison & Clayton, 2017) , but they were still excluded if pregnant or breastfeeding-a practice that is now regarded as unfair (Shields & Lyerly, 2013) . "Though deployed in the spirit of 'protection,' decisions to exclude pregnant women and their interests in the research agenda come at a profound cost for women and children alike" (Lyerly & Faden, 2013, p. 775) . Women and transgender parents need as equal an opportunity to participate in research as men in order to provide evidence about drug safety and efficacy.
Recently formed groups, for example, the Pregnancy Research Ethics for Vaccines, Epidemics, and New Technologies Working Group, include bioethics experts as well as stakeholders and clinical and policy experts to provide ethical guidance on the development of new vaccines for pregnant women (Krubiner et al., 2019) . In the United States, the FDA is currently developing guidance for industry that includes a section on the ethical considerations of clinical lactation studies and differentiates between women taking a drug for standard clinical care and women volunteering for studies of investigational drugs (U.S Department of Health and Human Services, 2019). The final guidance remains to be seen, but at least the discussion has moved on from a clearly unfair situation in which breastfeeding women were routinely excluded from drug trials. In Europe, a new publicprivate collaboration of 88 organizations from 22 countries has been established to tackle the knowledge gap in medication use for pregnant and breastfeeding women (BBMRI-ERIC, 2019) . In addition to using existing routinely collected data, the team will establish new human milk biobanks for research and develop novel pharmacokinetic techniques to improve understanding of medication use during lactation (BBMRI-ERIC, 2019).
Application of the concept of equity should ensure that vulnerable groups are not neglected and receive directly targeted interventions to improve their health outcomes (Abbasi et al., 2018) . Special populations that have been neglected in medication safety research include pregnant or breastfeeding parents and their children (Carpenter et al., 2017) . In the recent Phase 3 trials of brexanolone (a formulation of allopregnanolone)-a novel intravenous infusion treatment for moderate to severe postpartum depression-women were required to cease breastfeeding or agree to withhold human milk from their infant for a period of time up to 12 days from the beginning of treatment (Meltzer-Brody et al., 2018) . This is despite evidence from a Phase 1 study suggesting minimal infant risk due to low amount of brexanolone in human milk and low oral bioavailability (Hoffman et al., 2019) . Postpartum women are the market for this medication, and many will be breastfeeding; therefore this represents a critical missed opportunity for a thorough assessment of drug levels in human milk and, most importantly, their relationship to infant outcomes.
Assessing the Risks of Parental Medication Use Versus the Benefits of Their Own Milk
Given the lack of research pertaining to medications used during lactation, the concept of weighing risks and benefits can be challenging but is commonly used in reviews of medications for breastfeeding women. Recent examples include articles about risk-benefit assessment of infant exposure to lithium through mother's own milk (Newmark et al., 2019) and use of domperidone off-label as a galactagogue drug (Paul et al., 2015) . In a new review of medication use in breastfeeding women, Verstegen and Ito (2019) suggested the need for innovative simulated research techniques and concluded, "These efforts are important for rational risk assessment balancing the toxicity risk against the benefits of human milk" (p. 522). Verstegen and Ito explained that population pharmacokinetic modeling can be used for opportunistic samples to simulate estimates based on population pharmacokinetic parameters, as demonstrated in the article by Delaney et al. (2018) , which indicated that breastfed infants received no substantial exposure to escitalopram, used to treat depression and generalized anxiety disorder (Mayo Clinic, 2019), via human milk using this modeling.
For most medications, the potential for harming the breastfed infant is minimal; small amounts of medication are transferred into human milk and absorbed by the child (Rowe et al., 2013) . The importance of breastfeeding and human milk for infants, their families, and society is widely recognized (Victora et al., 2016) , and authors usually conclude their reviews with the recommendation that the benefits of medication use during lactation outweigh the risks (Newmark et al., 2019; Verstegen & Ito, 2019) .
Complicating this risk-benefit assessment is that we lack laboratory values for postpartum parents. Current laboratory values for thyroid function and liver function, for example, are for pregnant women or "normal" adults-there are no postpartum values to compare to during this period of their life (Stuebe et al., 2015) . Lack of relevant reference values can negatively influence medical care. For example, alkaline phosphatase (ALP) is produced by the placenta, and therefore levels rise consistently throughout pregnancy. Because laboratories have no normal range for postpartum women, clinicians may misinterpret elevated ALP results and incorrectly diagnose adverse hepatic drug reactions if monitoring liver function postpartum.
In considering utility, opinions about the use of medications during lactation vary depending on whose risk (or benefit) is prioritized, that of the infant or the parent (Newmark et al., 2019) . Risks include ill health in the lactating parent if medication is denied, ranging from mild discomfort all the way to fatality (Amir et al., 2012) . Stopping or withholding breastfeeding can lead to iatrogenic ill health in the parent, for example, mastitis if unable to remove milk efficiently. Risks to the infant of not breastfeeding include all the risks associated with exposure to milk from another species or mother, leading to both short-and long-term risks (Victora et al., 2016) .
Furthermore, the ethical concepts of empowerment and capacity building involve public education to educate consumers about informed choice and how to weigh risks and benefits of medication use (Abbasi et al., 2018) . Both clinicians and consumers poorly understand risk, and the process of decision making about medications for breastfeeding parents is complex (McClatchey et al., 2018) . Decisions to breastfeed are strongly influenced by cultural and social norms, as are decisions to protect the "innocent bystander" from potential harm (Saint-Raymond & de Vries, 2016, p. 21) . Parents are often socialized to believe that sacrificing their own well-being for that of their child is indicative of being a good parent (McClatchey et al., 2018) . They are also socialized, however, to take responsibility and care for themselves, acting on health care advice as provided by health professionals. These competing discourses challenge the process of informed decision making, particularly the capability to reason and exercise individual autonomy.
At present, health professionals need improved education about how to communicate risks and decision-making principles to their patients and clients (McCormack & Elwyn, 2018) . Research is also needed to improve risk communication about medications during lactation for both health professionals and consumers.
Provision of Evidence-Based Information by Health Care Professionals About Use of Medications for Breastfeeding Parents
Health professionals tend to rely on their own experiences of infant feeding when advising patients about breastfeeding (Svendby et al., 2016) , but this can no longer be considered reasonable behavior. It is vital that health professionals receive evidence-based education about the management of breastfeeding problems in order to best support new parents to achieve their breastfeeding goals (McClatchey et al., 2018) .
Fairness in public health policy includes "fair distribution of responsibilities, opportunities, resources, benefits and burdens with special attention to vulnerable groups, equal access to primary services and reduction of avoidable inequities through action on the social determinants of health" (Abbasi et al., 2018, p. 397) . This ethical concept implies that health should be accessible to all human beings, and therefore, infants should not be denied the normal start to life that breastfeeding provides. It is unfair for some infants to be denied human milk because health providers fail to provide evidence-based-or best-available-information regarding medications and advise premature cessation of breastfeeding unnecessarily (Davanzo et al., 2016; Wang et al., 2017) .
Conclusion
Medications for breastfeeding parents are commonly prescribed off-label and frequently without evidence about optimal dosing or treatment recommendations. This is largely because breastfeeding parents have been excluded from clinical trials and research studies, with traditionally risk-averse pharmaceutical companies facing a lack of incentives to ensure inclusion of this population group in product licensing. Hence the rights of breastfed infants and their families have been breached. The principles of fairness and equity have been hindered by pharmaceutical companies and health professionals providing inappropriate advice about medications and lactation, irrespective of actual evidence. There is a need for more multistakeholder engagement and deliberation on medications and lactation, involving not just clinicians but drug companies, health authorities, professional groups, and consumers.
